CLYM Quote, Financials, Valuation and Earnings

Mersana Therapeutics has a net margin of -- compared to Climb Bio's net margin of -86.29%. Climb Bio's return on equity of -- beat Mersana Therapeutics's return on equity of -533.43%.

Climb Bio has a consensus price target of $10.00, signalling upside risk potential of 640.74%. On the other hand Mersana Therapeutics has an analysts' consensus of $4.71 which suggests that it could grow by 914.04%. Given that Mersana Therapeutics has higher upside potential than Climb Bio, analysts believe Mersana Therapeutics is more attractive than Climb Bio.

Climb Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mersana Therapeutics has a beta of 1.667, suggesting its more volatile than the S&P 500 by 66.661%.

Climb Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mersana Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio pays -- of its earnings as a dividend. Mersana Therapeutics pays out -- of its earnings as a dividend.

Climb Bio quarterly revenues are --, which are smaller than Mersana Therapeutics quarterly revenues of $16.4M. Climb Bio's net income of -$8.9M is higher than Mersana Therapeutics's net income of -$14.1M. Notably, Climb Bio's price-to-earnings ratio is -- while Mersana Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio is -- versus 1.41x for Mersana Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Pyxis Oncology has a net margin of -- compared to Climb Bio's net margin of -20.17%. Climb Bio's return on equity of -- beat Pyxis Oncology's return on equity of --.

Climb Bio has a consensus price target of $10.00, signalling upside risk potential of 640.74%. On the other hand Pyxis Oncology has an analysts' consensus of $8.83 which suggests that it could grow by 695.8%. Given that Pyxis Oncology has higher upside potential than Climb Bio, analysts believe Pyxis Oncology is more attractive than Climb Bio.

Climb Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pyxis Oncology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Climb Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pyxis Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio pays -- of its earnings as a dividend. Pyxis Oncology pays out -- of its earnings as a dividend.

Climb Bio quarterly revenues are --, which are smaller than Pyxis Oncology quarterly revenues of $16.1M. Climb Bio's net income of -$8.9M is higher than Pyxis Oncology's net income of -$21.2M. Notably, Climb Bio's price-to-earnings ratio is -- while Pyxis Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio is -- versus -- for Pyxis Oncology. Usually stocks with elevated PS ratios are considered overvalued.

Sutro Biopharma has a net margin of -- compared to Climb Bio's net margin of -572.62%. Climb Bio's return on equity of -- beat Sutro Biopharma's return on equity of -99.41%.

Climb Bio has a consensus price target of $10.00, signalling upside risk potential of 640.74%. On the other hand Sutro Biopharma has an analysts' consensus of $7.89 which suggests that it could grow by 873.82%. Given that Sutro Biopharma has higher upside potential than Climb Bio, analysts believe Sutro Biopharma is more attractive than Climb Bio.

Climb Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sutro Biopharma has a beta of 1.219, suggesting its more volatile than the S&P 500 by 21.934%.

Climb Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sutro Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio pays -- of its earnings as a dividend. Sutro Biopharma pays out -- of its earnings as a dividend.

Climb Bio quarterly revenues are --, which are smaller than Sutro Biopharma quarterly revenues of $8.5M. Climb Bio's net income of -$8.9M is higher than Sutro Biopharma's net income of -$48.8M. Notably, Climb Bio's price-to-earnings ratio is -- while Sutro Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio is -- versus 0.36x for Sutro Biopharma. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of -- compared to Climb Bio's net margin of -549.33%. Climb Bio's return on equity of -- beat Voyager Therapeutics's return on equity of -21.07%.

Climb Bio has a consensus price target of $10.00, signalling upside risk potential of 640.74%. On the other hand Voyager Therapeutics has an analysts' consensus of $16.10 which suggests that it could grow by 312.82%. Given that Climb Bio has higher upside potential than Voyager Therapeutics, analysts believe Climb Bio is more attractive than Voyager Therapeutics.

Climb Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.991, suggesting its less volatile than the S&P 500 by 0.87699999999999%.

Climb Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

Climb Bio quarterly revenues are --, which are smaller than Voyager Therapeutics quarterly revenues of $6.3M. Climb Bio's net income of -$8.9M is higher than Voyager Therapeutics's net income of -$34.5M. Notably, Climb Bio's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio is -- versus 2.81x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.